These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12085827)

  • 21. Report from the 13th Conference on Retroviruses and Opportunistic Infections (CROI), February 5-8, 2006, Denver, Colorado.
    TreatmentUpdate; 2006; 18(2):4-6. PubMed ID: 17230629
    [No Abstract]   [Full Text] [Related]  

  • 22. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The metabolic toxicities of antiretroviral therapy.
    Herman JS; Easterbrook PJ
    Int J STD AIDS; 2001 Sep; 12(9):555-62; quiz 563-4. PubMed ID: 11516363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update of the DHHS antiretroviral treatment guidelines.
    Soriano V
    AIDS Rev; 2014; 16(2):117-8. PubMed ID: 24984766
    [No Abstract]   [Full Text] [Related]  

  • 25. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
    Mussini C; Bedini A; Borghi V; Guaraldi G; Esposito R; Barchi E; Enilia R; Cozzi-Lepri A; Philips AN; Ortolani P; Bratt G; Eriksson LE; Sighinolfi L; Cossarizza A; d'Arminio Monforte A; De Luca A; Di Giambenedetto S; Antinori A;
    AIDS; 2005 Feb; 19(3):287-94. PubMed ID: 15718839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Viral load and CD4+ lymphocyte count in the era of highly active antiretroviral therapy].
    Martín JC; Fernández P; Soriano V; Martínez P; González-Lahoz J
    Med Clin (Barc); 2000 Jun; 115(3):118. PubMed ID: 10965488
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV treatment interruptions: a review.
    Newcomb-Fernandez J
    Res Initiat Treat Action; 2003; 9(2):5-13. PubMed ID: 14989199
    [No Abstract]   [Full Text] [Related]  

  • 28. A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.
    Piroth L; Fournel I; Mahy S; Yazdanpanah Y; Rey D; Rabaud C; Faller JP; Hoen B; Fardeheb M; Quantin C; Chavanet P; Binquet C;
    Epidemiol Infect; 2011 Dec; 139(12):1835-44. PubMed ID: 21232172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV treatment series. Treatment interruptions. Reviewing what we've learned so far.
    Staszow K
    Posit Aware; 2006; 17(3):37-40. PubMed ID: 16791962
    [No Abstract]   [Full Text] [Related]  

  • 30. Structured treatment interruptions: after SMART.
    Sledge M
    BETA; 2006; 18(4):30-6. PubMed ID: 17019788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-HIV agents. An attempt at treatment interruption--trial CPCRA 064.
    TreatmentUpdate; 2003; 15(5):4-5. PubMed ID: 17216857
    [No Abstract]   [Full Text] [Related]  

  • 33. Anti-HIV agents. Is FOTO a treatment interruption that works?
    TreatmentUpdate; 2005; 17(5):10-1. PubMed ID: 17219661
    [No Abstract]   [Full Text] [Related]  

  • 34. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
    Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HAART version 2.0.
    Huff B
    GMHC Treat Issues; 2002 Mar; 16(3):1-4. PubMed ID: 12004795
    [No Abstract]   [Full Text] [Related]  

  • 38. Stopping antiretroviral therapy in 'prematurely treated' HIV-1-infected children with full viral supression is safe.
    Reula ES; León-Leal JA; Leal M; Obando I; Muñoz-Fernández A
    AIDS; 2006 Jan; 20(2):307-9. PubMed ID: 16511434
    [No Abstract]   [Full Text] [Related]  

  • 39. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PI/NRTI "sparing" regimens for HIV infection. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
    Cohen C
    IAPAC Mon; 2001 Aug; 7(8):254-60. PubMed ID: 11708281
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.